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ABSTRACT
Background and aims Nutritional support improves 
clinical outcomes during hospitalisation as well as 
after discharge. Recently, a systematic review of 27 
randomised, controlled trials showed that nutritional 
support was associated with lower rates of hospital 
readmissions and improved survival. In the present 
economic modelling study, we sought to determine 
whether in- hospital nutritional support would also return 
economic benefits.
Methods The current economic model applied cost 
estimates to the outcome results from our recent 
systematic review of hospitalised patients. In the 
underlying meta- analysis, a total of 27 trials (n=6803 
patients) were included. To calculate the economic impact 
of nutritional support, a Markov model was developed 
using transitions between relevant health states. Costs 
were estimated accounting for length of stay in a general 
hospital ward, hospital- acquired infections, readmissions 
and nutritional support. Six- month mortality was also 
considered. The estimated daily per- patient cost for in- 
hospital nutrition was US$6.23.
Results Overall costs of care within the model timeframe 
of 6 months averaged US$63 227 per patient in the 
intervention group versus US$66 045 in the control group, 
which corresponds to per patient cost savings of US$2818. 
These cost savings were mainly due to reduced infection 
rate and shorter lengths of stay. We also calculated the 
costs to prevent a hospital- acquired infection and a 
non- elective readmission, that is, US$820 and US$733, 
respectively. The incremental cost per life- day gained 
was −US$1149 with 2.53 additional days. The sensitivity 
analyses for cost per quality- adjusted life day provided 
support for the original findings.
Conclusions For medical inpatients who are 
malnourished or at nutritional risk, our findings showed 
that in- hospital nutritional support is a cost- effective way 
to reduce risk for readmissions, lower the frequency of 
hospital- associated infections, and improve survival rates.
INTRODUCTION
As a significant public health issue, malnu-
trition has detrimental effects on the care 
and recovery of hospitalised patients.1 If 
unrecognised or undertreated, impaired 
nutritional status can worsen health outcomes 
and escalate healthcare use and costs.2 3 Nutri-
tional shortfalls occur when unintended loss 
of weight and muscle result from collusion 
of various predisposing factors—older age, 
limited physical activity, insufficient protein 
and energy intake relative to needs, altered 
hormone function, and anorexia.4 Studies 
estimate that between 30% and 50% of adult 
inpatients are malnourished or at nutritional 
risk when admitted to hospital; nutritional 
risk is higher in patients who are older and 
have underlying chronic health conditions.5–7
The presence of malnutrition can impair 
a patient’s response to medical treatment 
and can increase susceptibility to hospital- 
acquired comorbidities, which include 
urinary tract infections, falls and fractures, 
acute respiratory infections, skin tears, and 
hospital- acquired pressure injuries.8–10 As a 
result, malnutrition in a hospitalised adult 
can hinder the patient’s recovery, prolong 
length of hospital stay, and increase the need 
for postdischarge institutional care.8–11
Not surprisingly, the high prevalence and 
adverse effects of malnutrition in hospitalised 
Strength and limitations of this study
 ► Large data set of randomised nutritional trials based 
on a recent systematic reviewand meta- analysis.
 ► Different patient- relevant outcomes considered in 
the cost analyses.
 ► Calculation of costs and cost savings from the per-
spective of the 27 hospitals included in the underly-
ing meta- analysis which limit generalisability.
 ► Focusing on direct costs as the main drivers of eco-
nomic decision, but not on costs associated with 
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patients affect the overall cost of healthcare in the USA, 
as in the rest of the world. The estimated annual cost of 
disease- associated malnutrition in the USA is over US$15.5 
billion.7 In Canada, the added cost of in- hospital care for 
a malnourished patient is US$1500–2000 per hospital 
stay (compared with the cost for an adequately nourished 
patient); this translates to an excess US$1.56–2.1 billion 
per year, similar to the US when adjusted for population.5 
Studies from Latin America estimate an annual costs 
of US$10.2 billion for management of malnourished 
patients in public hospitals,12 13 and studies from Europe 
and Asia likewise report markedly higher costs for care of 
malnourished hospital patients.14–18
Identifying and treating malnutrition are critical to 
improving patient health outcomes and to reducing 
healthcare costs.6 To identify and manage hospitalised 
patients at risk for malnutrition, nutrition- focused quality 
improvement programmes can be used to guide nutrition 
screening and assessment, to intervene with nutrition care 
when needed, and to provide ongoing monitoring and 
adjustment of nutrition, as needed.19 20 Such programmes 
improved patient outcomes and decreased healthcare 
costs, as evidenced by reduced rates of hospital- acquired 
infections, shorter lengths of hospital stay, and lower 
rates of readmission.19 21–24 A systematic review of studies 
using oral nutritional supplements to treat malnutrition 
revealed cost savings, which were attributed to fewer 
medical complications, shortened hospital stays, preven-
tion of pressure ulcers, and improved quality- adjusted 
life years.25 A large clinical trial on use of individual-
ised nutritional support during hospitalisation showed 
improved nutritional intake, functional outcome, and 
quality of life, along with lowered risk of adverse effects 
and decreased 30- day mortality.26 Results of the follow- on 
economic- evaluation study demonstrated cost savings 
related to reduced intensive care unit stays and fewer 
hospital- acquired complications.27
Gomes et al recently conducted a systematic review of 
27 trials of patients who were malnourished or at risk 
of malnutrition on admission to the hospital.4 Results 
showed that in- hospital nutritional support could signifi-
cantly improve patient outcomes by increasing patients’ 
energy and protein intake, which was associated with 
weight gain, lowered mortality rates, and reduced rates of 
non- elective hospital readmissions.4 Based on these find-
ings, the aim of our current analysis was to use economic 
modelling to predict whether benefits of in- hospital 
nutritional support are accompanied by returns in terms 
of economic benefits. In modelling, we also considered 
other Gomes et al endpoints that showed a clinically 
meaningful improvement, that is, lowered infection rates 
and shorter length of stay in hospital.4
METHODS
To clarify the current economic modelling analysis, we 
provide definitions of health economic terms used in 
our report (table 1).28 Our model examined costs and 
potential cost benefits of using nutritional support for 
hospitalised patients. Nutritional support includes (1) 
screening admitted patients for malnutrition or its risk, 
(2) for those identified, systematic nutritional assessment 
by a dietitian, including recommendations for nutritional 
targets, (3) development of an individualised nutritional 
care plan, including implementation and follow- up.26 29
Economic modelling and analysis
For our Markov model, we assumed that all patients were 
in a stable health state—hospitalised and malnourished 
(figure 1). Thereafter, patients could develop major 
infections. This was modelled as a separate health state 
because the probability of death, as well as healthcare costs 
and utilisation, were assumed to be higher in compar-
ison with patients not experiencing in- hospital compli-
cations. In another state, patients could be discharged 
from the hospital. Following discharge, patients may 
require unplanned readmission to the hospital. Finally, 
patients have different probabilities of death in each 
state, depending on their health status.
Table 1 Definition of terms for health economic analyses
Markov model A model used for randomly changing systems. Applied to healthcare, Markov models assume that a 
patient is in one of a finite number of discrete health states, for example, inpatient with malnutrition, 
inpatient with infectious complication, patient discharged from hospital, or patient readmitted to hospital 
non- electively. In modelling, the patient transitions from one state to another, with death as an unalterable 
state.
Cost effectiveness Value for the cost. In healthcare, the goal is to maximise the benefit of treatment for a patient population 
while using limited resources.
Incremental Cost- 
Effectiveness Ratio (ICER)
Used in health economics to compare two different interventions in terms of the cost of gained 
effectiveness. ICER is computed by dividing the difference in cost of 2 interventions by the difference of 
their effectiveness, for example, if treatment A costs US$50 per patient and provides 2 quality- adjusted 
life days (QALDs), and treatment B costs US$80 while providing 3 QALDS, the ICER of treatment B is 
US$80-50/3-2 = US$30.
The ICER determination is also called a cost–utility analysis.
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We modelled the economic impact of the nutritional 
support from a payer’s perspective. To do so, we devel-
oped a Markov cohort model with daily cycles.28 30 The 
timeframe for our model was 6 months, consistent with 
results reported in the meta- analysis by Gomes et al.4 
We applied utility values (cost of gained effectiveness of 
nutritional support) that were derived from a study by 
Schuetz et al, assuming the utility value for preventing an 
in- hospital adverse event was a reasonable proxy for devel-
oping an infection during hospitalisation.27 Likewise, we 
applied a utility value from Harvey et al for preventing 
non- elective readmission.31 Additionally, we assumed that 
the utility value for a released patient was 10% higher than 
for a patient in the stable health state. A more detailed 
description of the methods and assumptions is provided 
in online supplemental appendix A.1. We assumed costs 
for the various health states as follows: (1) no cost for 
patients released from hospital, (2) costs for nutritional 
support and readmission were sourced from the Nutri-
tion effect On Unplanned Readmissions and Survival in 
Hospitalised patients (NOURISH) health economic anal-
ysis,32 assuming SD as 10% of the input value, (3) costs for 
a heterogeneous distribution of infections were estimated 
on the basis of US hospital infection costs reported,33 (4) 
no cost for death, and (5) the cost of nutritional support 
as reported previously.34
The primary outcomes in our model were cost- by- 
health- state and total cost. We calculated days in each 
health state, and we calculated utility value as the differ-
ence between the total costs of individualised nutritional 
support compared with no support. Individualised nutri-
tional support refers to patient screening, assessment, 
definition of individual nutrition goals (including energy 
and protein, micronutrients) and a nutritional protocol 
to reach these goals (including oral nutritional supple-
ments). The estimated daily per- patient cost for in- hos-
pital nutrition was US$6.23. Because we modelled real- life 
findings, we did not apply discount rates to any costs and 
outcomes.35–37 Sensitivity analyses were executed on key 
variables of the model, including probability of patient 
release from hospital, cost for infections, cost for general 
ward hospitalisation, and cost for individualised nutri-
tional support. Because costs of nutritional supplements 
may vary in different care sites, we performed a sensitivity 
analysis to determine whether cost savings would be main-
tained when nutritional supplement costs) were US$3 per 
day (lower bound), US$4 per day (medium), and US$6 
per day (upper bound).
To optimise our reporting of health economic evalua-
tions, we used the Consolidated Health Economic Evalu-
ation Reporting Standards checklist.38
Patient and public involvement
The data used for this study are based on a previous meta- 
analysis and as a result, patients were not involved in 
the design and conduct of the study, choice of outcome 
measures or recruitment to the study. However, we 
discussed the study concept and economic models before-
hand in our multiprofessional team consisting of physi-




The original systematic review included a total of 27 
trials with 6803 patients.4 Compared with patients in the 
control group, those who received nutritional support 
had a significantly lower mortality rate (230 of 2758 
(8.3%) vs 307 of 2787 (11.0%) with an OR of 0.73 (95% 
CI 0.56 to 0.97)).
Costs and cost-benefits of nutritional intervention
A base- case analysis summarises our cost results (table 2). 
Here, ‘Life’ represents the number of patient lives in 
each health state. Utilities results are shown as quality- 
adjusted life days (QALD), which were calculated in the 
model. Finally, the calculated cost for each health state 
is shown. The per- patient cost for in- hospital nutritional 
support was estimated at US$36.44 per patient across the 
patient’s hospital length of stay. In terms of costs over the 
6- month timeframe of the study model, hospital care aver-
aged US$63 227 per patient in the nutrition- intervention 
group versus US$66 045 in the control group. Sensi-
tivity analysis within a range of US$3–6 per day cost for 
the nutritional supplement did not overcome the cost- 
benefit for nutritional support (total cost US$105,632 for 
US$4 US$105,681 for US$6 in the nutritional support, 
respectively).
Incremental differences in cost savings, life days, 
QALDs, and Incremental Cost- Effectiveness Ratio 
(ICER) per life days were determined (table 3). When 
using nutritional support, the total cost savings over the 
6- month modelling interval was US$2912, which was 
mainly driven by cost savings in the general ward hospital-
isation (US$2818). Patients receiving nutritional support 
Figure 1 Health states within the Markov model. 
Designations of health states were based on findings in the 
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also had 2.5 more life days without complications during 
the modelled time. Finally, given the cost savings and the 
added life days, cost- effectiveness results show dominance 
for the nutritional support group.
We also calculated costs to prevent hospital- acquired 
infections and hospital readmission, which were US$820 
for one prevented infection and US$733 for one prevented 
non- elective readmission. The incremental cost per life 
day gained was -US$1149 with 2.53 additional days. When 
varying the input values, the results of the sensitivity anal-
yses provided support for the original findings.
DISCUSSION
When hospitalised patients with malnutrition or at nutri-
tional risk receive nutritional support, risk for hospital 
infections is reduced, length of stay is shortened, and the 
likelihood of hospital readmission is decreased. Impor-
tantly, results of our current modelling study showed that 
the added cost of providing nutritional support is low, 
especially when considering the associated reductions in 
costs of hospitalisation and medical treatments. Taken 
together, results from our present Markov health cost 
modelling showed that in- hospital nutritional support is a 
highly cost- effective intervention.
Comparison with findings in other nutrition care studies
The underlying systematic review by Gomes et al found 
that nutritional support led to statistically significant 
reductions in mortality and non- elective hospital read-
missions,4 findings that have also been reported for 
other hospital populations.4 21 23 24 26 39 As well, the 
results of our health economic modelling analysis 
confirmed and extended data and messages on the 
‘value of nutrition’ in care for hospitalised patients in 
North America,40 41 Latin America,13 42 43 Europe and the 
UK,25 44–46 and Asia.17 34
Hospital nutritional care has proven particularly effica-
cious and cost effective in older populations with multiple 
health conditions, including those living in different care 
settings—in the community44 47–49 and in nursing care 
facilities.47 50 Furthermore, it was recently shown that 
malnutrition is underdiagnosed in emergency depart-
ments, also leading to a higher burden in terms of health-
care costs.51
Table 2 Base- case results
Patient state















11.49 12.00 0.022 0.023 63 227 66 045
Non- elective 
readmission
0.14 0.17 0.000 0.000 193 237
In- hospital with 
Infection
0.52 0.60 0.001 0.001 4554 5374
Discharged from 
hospital
162 159 0.342 0.333 37 597 36 863
Death 7.74 10.27
Total
(sum of health states 
above)
174.26 171.73 0.365 0.358 105 608 108 520
QALDs, Quality- Adjusted Life Days.
Table 3 Results for incremental differences from base- case analysis
Cost item
Incremental changes for nutritional support versus no nutritional support
Cost savings, US$ Life days QALDs ICER LD, US$
General ward hospitalisation 2818.17 0.51 −0.0009 −5569.72
Readmission 43.50 −0.03 −0.0001 1372.62
Infections 820.89 0.09 0.0001 −8891.82
Released 733.65 3.16 0.0081 231.92
Death −2.53
Total 2912.47 2.53 0.0070 −1149.63
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Limitations of this modelling analysis
As for all modelling analyses, our model had some limita-
tions. Costs and cost savings were calculated from the 
perspective of the 27 hospitals included in the Gomes 
et al review and meta- analysis4; results may thus not be 
fully generalisable to hospitals where patient demo-
graphics, disease severity, and care costs differ markedly 
from those in the reviewed studies. As well, our modelled 
cost- savings calculations reflect reductions in infectious 
complications, hospital length of stay, and non- elective 
readmissions, as measures for the effectiveness of in- hos-
pital nutritional support. Other clinical outcomes, such 
as non- infective complications, are not included in the 
evaluation but could be included in future studies on 
hospital- related costs. Additionally, our model used direct 
costs as the main drivers of economic decision- making 
from the perspective of US hospital administrators and 
payers; future models could tackle savings in cost terms 
important to the patients, such as faster recovery with less 
disability and lower loss of work productivity.
The way forward
Guidelines and recommendations on the importance 
of nutrition care for medical nutritionally vulnerable 
inpatients are increasingly available in the US and else-
where.3 35 52–54 A recent European study showed that 
adherence to guidelines on malnutrition management in 
15 hospitals was generally good, which led to improved 
nutritional care in hospitals.55 Based on our modelled 
findings, we anticipate that increased attention to nutri-
tional support during and after hospitalisation may yield 
marked benefits both in terms of health outcomes and 
cost savings.
CONCLUSION
In conclusion, our modelling analysis predicted that 
in- hospital nutritional support for medical inpatients who 
are malnourished or at nutritional risk can yield signifi-
cant cost- benefits along with previously reported gains in 
terms of health outcomes.4 Together, these positive effects 
provide a compelling rationale for hospitals to follow 
comprehensive nutrition care pathways—including 
screening for malnutrition risk, assessment of causes 
and severity of malnutrition, and provision of nutrition- 
focused support during and after hospitalisation.52 53 56
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